For in vitro diagnostic use. Others cobas MPX Multiplex HIV HCV and HBV 58-68-88 IVD cobas® MPX PID00000024 Multiplex HIV, HCV & HBV nucleic acid test for use on the cobas® 5800/6800/8800 systems 09 040 862 190 9 040 862 190 09040862190 9040862190 09040862190 KIT COBAS 58/68/8800 MPX 480T IVD cobas MPX 00875197006452 Reagents, kits 1 Kit 480 tests true 09 040 854 190 9 040 854 190 09040854190 9040854190 09040854190 KIT COBAS 58/68/8800 MPX 480T US-IVD KIT COBAS 58/68/8800 MPX 480T US-IVD 00875197007107 Reagents, kits 1 Kit 480 tests true 09 288 538 190 9 288 538 190 09288538190 9288538190 09288538190 KIT COBAS 58/68/8800 MPX 192T CE-IVD KIT COBAS 58/68/8800 MPX 192T CE-IVD 00875197006728 Reagents, kits 1 Kit 192 tests true The cobas® MPX test, for use on cobas® 5800/6800/8800 systems is a qualitative in vitro test for the direct detection of Human Immunodeficiency Virus Type 1 (HIV1) Group M RNA, HIV-1 Group O RNA, Human Immunodeficiency Virus Type 2 (HIV-2) RNA, Hepatitis C Virus (HCV) RNA, and Hepatitis B Virus DNA in human plasma and serum. This test is intended for use to screen donor samples for HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA, HCV RNA, and HBV DNA in plasma and serum samples from individual human donors, including donors of whole blood, blood components, and other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor's heart is still beating and in testing of cadaveric (non-heart beating) donors. Plasma and serum from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma and serum samples may be tested individually or plasma may be tested in pools comprised of aliquots of individual samples. For donations from cadaveric (non-heart beating) organ and tissue donors, samples may only be screened as individual samples. For an individual sample, results are simultaneously detected and discriminated for HIV, HCV, and HBV. The cobas® MPX test can be considered a supplemental test that confirms HIV infection for samples that are repeatedly reactive on a CE-IVD test for antibodies to HIV and reactive on the cobas® MPX test. The cobas® MPX test can be considered a supplemental test that confirms HCV infection for samples that are repeatedly reactive on a CE-IVD test for antibodies to HCV and reactive on the cobas® MPX test. The cobas® MPX test can be considered a supplemental test that confirms HBV infection for samples that are repeatedly reactive on a CE-IVD test for Hepatitis B surface antigen and reactive on the cobas® MPX test. This test may also be used as an aid in diagnosis of HIV, HCV, or HBV in samples collected from individuals suspected of infection with these viruses by their healthcare provider or to screen individuals whose infection status for HIV, HCV or HBV is unknown. en cobas® MPX, for use on cobas® 6800 and cobas® 8800 Systems, is a qualitative in vitro nucleic acid test for the direct detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M RNA, HIV-1 Group O RNA, Human Immunodeficiency Virus Type 2 (HIV-2) RNA, Hepatitis C Virus (HCV) RNA, and Hepatitis B Virus (HBV) DNA in human plasma and serum. The cobas® MPX test simultaneously detects and discriminates for HIV, HCV, and HBV. The assay does not discriminate between HIV-1 Group M, HIV-1 Group O, and HIV-2.This test is intended for use to screen donor samples for HIV-1 Group M RNA, HCV RNA, and HBV DNA in plasma and serum samples from individual human donors, including donors of Whole Blood, blood components, Source Plasma and other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor's heart is still beating or from cadaveric (non-heart beating) donors. Plasma and serum from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma and serum samples may be tested individually or plasma may be tested in pools comprised of not more than six individual samples. For donors of hematopoietic stem/progenitor cells (HPCs) sourced from bone marrow, peripheral blood or cord blood, and for donors of donor lymphocytes for infusion (DLI), plasma may be tested in pools comprised of not more than six individual samples. For donations of source plasma, samples may be tested in pools comprised of not more than 96 individual samples. For all other donors, samples may only be screened as individual samples.This test is intended to be used in conjunction with licensed serology tests for HIV-1, HCV, and HBV.This test is not intended for use as an aid in diagnosis of HIV, HCV, or HBV.This test is not intended for use on samples of cord blood.cobas® MPX can be considered a supplemental test that confirms HIV infection for specimens that are repeatedly reactive on a licensed donor screening test for antibodies to HIV and reactive for HIV on the cobas® MPX tests.cobas® MPX can be considered a supplemental test that confirms HCV infection for specimens that are repeatedly reactive on a licensed donor screening test for antibodies to HCV and reactive for HCV on the cobas® MPX tests.cobas® MPX can be considered a supplemental test that confirms HBV infection for specimens that are repeatedly reactive on a licensed donor screening test for Hepatitis B surface antigen, and reactive for HBV on the cobas® MPX test. en cobas® MPX, for use on cobas® 5800/6800/8800 Systems is a qualitative in vitro nucleic acid screening test for the direct detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M RNA, HIV-1 Group O RNA, Human Immunodeficiency Virus Type 2 (HIV-2) RNA, Hepatitis C Virus (HCV) RNA, and Hepatitis B Virus (HBV) DNA in human plasma and serum. This test is intended for use to screen donor samples for HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA, HCV RNA, and HBV DNA in plasma and serum samples from individual human donors, including donors of whole blood, blood components, source plasma and other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor's heart is still beating and in testing of cadaveric (non-heart beating) donors. Plasma and serum from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma and serum samples may be tested individually or plasma may be tested in pools comprised of not more than six individual samples. For donors of hematopoietic stem/progenitor cells (HPCs) sourced from bone marrow, peripheral blood or cord blood, and for donors of donor lymphocytes for infusion (DLI), plasma may be tested in pools comprised of not more than six individual samples. For donations of source plasma, samples may be tested in pools comprised of not more than 96 individual samples. For donations from cadaveric (non-heart beating) organ and tissue donors, samples may only be screened as individual sample. This test is intended to be used in conjunction with licensed serology tests for HIV, HCV, and HBV. For an individual sample, results are simultaneously detected and discriminated for HIV, HCV, and HBV. cobas® MPX can be considered a supplemental test that confirms HIV-1 infection for samples that are repeatedly reactive on a licensed donor screening test for antibodies to HIV-1 and reactive for HIV on cobas® MPX. cobas® MPX is not intended to be used as a supplement test to confirm HIV-2 infection. cobas® MPX can be considered a supplemental test that confirms HCV infection for samples that are repeatedly reactive on a licensed donor screening test for antibodies to HCV and reactive for HCV on cobas® MPX. cobas® MPX can be considered a supplemental test that confirms HBV infection for samples that are repeatedly reactive on a licensed donor screening test for Hepatitis B surface antigen and reactive for HBV on cobas® MPX. This test is not intended for use as an aid in diagnosis of HIV, HCV, or HBV. This test is not intended for use on samples of cord blood. en The cobas® MPX test is based on real time PCR technology with fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection on the system. The cobas® 5800 system consists of a single, integrated instrument. The cobas® 6800/8800 systems consists of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 5800 or 6800/8800 system software which assigns test results for all tests as non-reactive, reactive, or invalid. When using the cobas® 5800/6800/8800 systems, results can be reviewed directly on the system screen, printed as a report , or sent to a LIMS or other result management system. Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. If pooling is to be performed, cobas® Synergy software with the Hamilton MICROLAB® STAR/STARlet IVD may optionally be used in a pre-analytical step. Nucleic acid from the sample and added armored RNA internal control (IC) molecules (which serve as a full process control from sample preparation through amplification/detection) is simultaneously extracted. The IC monitors for interference that could cause false negative results. Potentially affected samples are invalidated. In addition the test utilizes four external controls: three positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid bind s to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature. Selective amplification of target nucleic acid from the sample is achieved by the use of virus -specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. For HIV-1 Group M two different regions of the viral genome are amplified (dual target). A thermostable DNA polymerase enzyme is used for both reverse - transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorp orated into the newly synthesized DNA (amplicon).33-35 Any contaminating amplicons from previous PCR runs are eliminated by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR master mix, when heated in the first thermal cycling step. However, newly formed amplicons are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55 °C. The cobas® MPX master mix contains detection probes which are specific for HIV -1 (Groups M and O), HIV -2, HCV, HBV, and IC nucleic acid. Detection probes for each HIV -1 Group M target are included, along with dual probes for HCV. The specific HIV, HCV, HBV, and IC detection probes are each labeled with one of four unique fluorescent dyes which act as a reporter. Each probe also has a fifth dye which acts as a quencher. The four reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HIV, HCV, and HBV targets and the IC.36,37 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single -stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the four specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HIV, HCV and HBV targets and the IC are possible. 33. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-8. PMID: 2227421. 34. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-93. PMID: 7845459. 35. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-78. PMID: 7697717. 36. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y). 1992;10:413-7. PMID: 1368485. 37. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94. PMID: 8908518. en cobas® MPX is based on real time PCR technology on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection system. The cobas® 6800/8800 Systems consists of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report, or sent to a Laboratory Information Management System (LIMS) or other result management system.Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. The cobas® Synergy software with the Hamilton MICROLAB® STAR IVD, may optionally be used in a pre-analytical step if pooling is to be performed.Nucleic acid from the sample and added armored RNA internal control (IC) (which serve as the sample preparation and amplification/detection process control) is simultaneously extracted. In addition the test utilizes four kit controls: three positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. For HIV-1 Group M, two different regions of the viral genome are amplified (dual target). A thermostable DNA polymerase enzyme is used for both reverse- transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). 33-35 Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR master mix, when heated in the first thermal cycling step. However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® MPX master mix contains detection probes which are specific for HIV-1 (Groups M and O), HIV-2, HCV, HBV, and IC nucleic acid. Detection probes for each HIV-1 Group M target are included along with dual probes for HCV. The specific HIV, HCV, HBV, and IC detection probes are each labeled with one of four unique fluorescent dyes which act as a reporter. Each probe also has a fifth dye which acts as a quencher. The four reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HIV, HCV, and HBV targets and the IC. 36,37 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the four specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HIV, HCV and HBV targets and the IC are possible.33. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-8. PMID: 22274234. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-93. PMID: 7845459.35. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-78. PMID: 7697717.36. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y). 1992;10:413-7. PMID: 1368485.37. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94. PMID: 8908518. en cobas® MPX is based on real time PCR technology on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection system. The cobas® 5800 System consists of a single, integrated instrument. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 5800 or 6800/8800 System software which assigns test results for all tests as non-reactive, reactive, or invalid. When using the cobas® 5800 System, the cobas® Synergy software is recommended for reviewing results and printing reports, and it is required to send results to a Laboratory Information Management System (LIMS) or other result management system. When using the cobas® 6800/8800 Systems, results can be reviewed directly on the system screen, printed as a report, or sent to a LIMS or other result management system. Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. When testing on cobas® 5800 Systems, use of the cobas® Synergy software is required even if pooling is not performed. If pooling in a pre-analytical step is performed, cobas® Synergy software with the Hamilton MICROLAB® STAR/STARlet IVD may be used. When testing on the cobas® 6800/8800 Systems, the cobas® p 680 instrument, or cobas® Synergy software with the Hamilton MICROLAB® STAR/STARlet IVD, may optionally be used in a pre-analytical step if pooling is to be performed. Nucleic acid from the sample and added armored RNA internal control (IC) molecules (which serve as the sample preparation and amplification/detection process control) is simultaneously extracted. In addition the test utilizes four external controls: three positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature. Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. For HIV-1 Group M two different regions of the viral genome are amplified (dual target). A thermostable DNA polymerase enzyme is used for both reverse- transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). 33-35 Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR master mix, when heated in the first thermal cycling step. However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C. The cobas® MPX master mix contains detection probes which are specific for HIV-1 (Groups M and O), HIV-2, HCV, HBV, and IC nucleic acid. Detection probes for each HIV-1 Group M target are included, along with dual probes for HCV. The specific HIV, HCV, HBV, and IC detection probes are each labeled with one of four unique fluorescent dyes which act as a reporter. Each probe also has a fifth dye which acts as a quencher. The four reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HIV, HCV, and HBV targets and the IC. 36,37 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the four specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HIV, HCV and HBV targets and the IC are possible. 33. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-8. PMID: 2227421. 34. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-93. PMID: 7845459. 35. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-78. PMID: 7697717. 36. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y). 1992;10:413-7. PMID: 1368485. 37. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94. PMID: 8908518. en

User profile

Select your user profile

cobas^® MPX

Overview

Ordering information

Technical documents

Access important product documentation including relevant certificates and other resources.

Compatible products

Related products

Contact us